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Abstract
Background: Luteal-phase support is a complex and controversial issue in the field of
reproductive management.
Objective: To compare the safety and efficacy of low-dose subcutaneous progesterone
with the vaginal progesterone for luteal-phase support in patients undergoing rozen-
thawed embryo transfer.
Materials and Methods: In this cross-sectional study, information related to 77 women
that had frozen-thawed embryo transfer was reviewed. The patients were divided into
two groups based on the route of progesterone administration used as a luteal-phase
support. When the endometrial thickness reached ≥ 8 mm, in one group progesterone
(Prolutex) 25 mg/ daily subcutaneous and in another group, vaginal progesterone
(Cyclogest®) 400 mg twice or (Endometrin®) 100 mg thrice daily, were administrated
and continued until menstruation or in case of clinical pregnancy for 8 wk after the
embryo transfer when the fetal heart activity was detected by ultrasonography.
Results: The patient’s characteristics were matched and there was no significant
difference. The chemical and clinical pregnancy rate was higher in the vaginal
progesterone group compared to the prolutex group, but statistically unnoticeable,
(40% vs. 29.6%, p = 0.367) and (28% vs. 22.2%, p = 0.581), respectively.
Conclusion: The findings of this study demonstrate that the new subcutaneous
progesterone can be a good alternative for intramuscular progesterone in women
that dislike and do not accept vaginal formulations as luteal-phase support in assisted
reproductive technology.
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1. Introduction
Additional embryos obtained through in vitro
fertilization (IVF) or intracytoplasmic sperm
injection can be stored and transferred in
frozen-thawed cycles to prevent the waste of
embryo and raises the chance of pregnancy
in a single stimulated cycle (1). Various factors
such as patient’s age, endometrial thickness and
pattern, progesterone administration, quality,
and the development stage of the embryo,
cryopreservation methods affect the factors of
pregnancy outcomes (2). Despite the crucial
role of progesterone in the luteal phase, based
on the route of administration, it has different
pharmacological efficacy (3). The different types
of progesterone administration include oral,
vaginal, oil-based intramuscular (IM) and new
aqueous subcutaneous (SC) progesterone.
Oral progesterone has poor bioavailability
with limited usage in infertility management
due to extensive first-pass metabolism in liver.
Vaginal progesterone notwithstanding lower
circulating levels reaches sufficient endometrial
concentration and has good efficiency, but a
number of side effects such as vaginal discharge
or local irritation, discomfort, and doubt about
sufficient absorption has reduced its compliance.
Furthermore, because of the apprehensions
stemming from different cultural beliefs and
personal concerns, many patients avoid the
consumption of vaginal progesterone. Beside,
oil-based IM progesterone has a fixed dosage
but can be really painful, even forming sterile
abscesses in some cases (4).
A novel water-soluble SC progesterone
(Prolutex) is a good alternative for IM
progesterone, it is offered because of equal
pharmacokinetic effect to IM P and its additional
appropriate self-administration. Although, many
studies have proven the safety and efficacy of
Prolutex, very few have demonstrated patients’
acceptance and opinions about it (5). Prolutex is a
synthesis of P and hydroxypropyl-b-cyclodextrin in
water that administers SC in a daily dose of 25 or
50 mg. No difference was seen in the endometrial
biopsies in the menstrual cycle between the
two doses when endogenous progesterone
suppressed (6). A study established that the least
dose of SC progesterone (25 mg) has equal effect
to the daily amount of physiologic of progesterone
that produced by the ovary in mid-luteal phase
and predecidual changes have seen in all of the
endometrium samples (7). Therefore, rather than
the 50 or 100 mg doses, we chose the lowest
dose in our examination for luteal-phase support
(LPS), which demonstrated fewer skin reactions
and more safety (8).
The purpose of this study was to compare
the safety and efficacy of the low-dose SC
Progesterone with the vaginal progesterone for
LPS in patients undergoing frozen-thawed embryo
transfer (FET).
2. Materials and Methods
This cross-sectional study was conducted at
the Yazd Reproductive Sciences Institute and
the Madar Hospital in Yazd. Data were obtained
from the assisted reproductive technology (ART)
database over a sixmonths period betweenMarch
and September 2019. In this study, the medical
records of 77 women was retrieved and reviewed.
All women included in this study had
previously undergone IVF or intracytoplasmic
sperm injection cycles and had embryo
cryopreservation. Women aged > 40 yr, with body
mass index (BMI) > 30 kg/m2, history of diabetes
mellitus and hypertension, severe endometriosis,
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uterine myomatosis, > 2 implantation failures
were excluded from the study. Based on the
LPS protocol, the patients were divided into
two groups: group I (n = 27) that received
Prolutex 25 mg (IBSA Institut Biochimique
SA, Switzerland) and group II (n = 50) that
used vaginal progesterone Cyclogest® (Cox
Pharmaceuticals, Barnstaple, UK) or Endometrin®
(Ferring Pharmaceuticals Inc., Parsippany, NJ,
USA). We used 6 mg/day orally Estradiol valerate
(Estradiol Valerate, Aburaihan Co., Tehran, Iran)
for Endometrial preparation in both groups from
the second day of the menstrual cycle. Ultrasound
was done from day 13, endometrial thickness was
measured at the maximum diameter in the fundal
section.
When the endometrial thickness reached ≥ 8
mm, women in group I received SC progesterone
(Prolutex 25 mg; IBSA Institut Biochimique SA,
Switzerland) and those in group II received
vaginal progesterone (Cyclogest® 400 mg twice
or Endometrin® 100 mg thrice) daily until negative
pregnancy test or for 8 wk after embryo transfer
until a fetal heart activity was detected by
ultrasound. The embryos were thawed two
days after the start of progesterone consumption.
Embryo transfer was conducted in cleavage-stage
one day after the thawing was performed under
ultrasound guidance. Two good-quality embryos
(grade A, and B) were transferred to each group
using a Cook catheter (Cook Medical, Indiana,
USA). A positive pregnancy test was defined
as β-hCG > 50 IU/L 14 days after the embryo
transfer that was called chemical pregnancy.
Secondary outcomes included: Definition of
clinical pregnancy is revealing of fetal heart
activity in transvaginal ultrasonography 2-3 wk
after the positive β-HCG; implantation rate is the
ratio of gestational sacs to the number of embryos
transferred.
In addition, an abortion was defined as the
loss of pregnancy before the 20th wk of gestation
while an ongoing pregnancy was considered as
a pregnancy continuing beyond the 12th wk of
gestation.
2.1. Ethical considerations
This study was approved by the Ethics
Committee of the Yazd Reproductive Sciences
Institute, Shahid Sadoughi University of Medical
Sciences, Yazd, Iran (IR.SSU.RSI.REC.1398.027).
2.2. Statistical analysis
We analyzed the data by using the statistical
package for the social science version 26 for
windows (SPSS Inc., Chicago, IL, USA). A student’s
t test was apply to assess other variables. We
used The Chi-square test for comparition the
non-continuous variables. A P-value < 0.05 is
statistically significant.
3. Results
This study was conducted on 77 women, of
which 27 patients were included in the Prolutex
group and 50 in the vaginal progestrone group
(Table I). No statistically significant difference was
observed between the two groups (Table I). The
patients were selected from different infertility
etiologies and there was no difference between
them (Table II). The clinical results showed that
chemical and clinical pregnancy rates were higher
in the vaginal P group than the prolutex group but
the difference was statistically insignificant (40%
vs. 29.6%, p = 0.367) and (28% vs. 22.2%, p =
0.581), respectively (Table III).
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Table I. Comparison of patient’s characteristics between the two groups
Patients characteristics Prolutex group (n = 27) Vaginal progestrone group (n = 50) P-value CI (95%)
Age (yr) 29.48 ± 4.79 31.30 ± 4.35 0.096 (-3.96-0.32)
BMI (kg/m2) 23.73 ± 2.03 23.13 ± 1.66 0.168 (-2.58-1.45)
Infertility duration (yr) 5.55 ± 3.35 5.600 ± 2.86 0.951 (-1.49-1.40)
AMH (ng/ml) 2.62 ± 1.45 2.61 ± 1.20 0.960 (-0.60-0.63)
Total embryo 7.51 ± 4.29 6.18 ± 3.14 0.122 (-0.36-3.04 )
Endometrial thickness (mm) 9.75 ± 1.15 9.26 ± 0.85 0.055 (0.37-0.95 )
Transfer day 17.3 ± 1.30 16.9 ± 0.88 0.088 (-0.65-0.93)
Data are presented as Mean ± SD, Student t test, CI: Confidence interval, AMH: Anti-Mullerian hormone, BMI: Body mass index
Table II. Comparison of different etiologies between the two groups
Variables MF PCO OF TF Unexplained Mixed P-value
Prolutex group 6 (22) 4 (14) 8 (29) 2 (7) 0 (0) 7 (25)
Cyclogest group 12 (24) 5 (10) 11 (22) 5 (10) 7 (14) 10 (20)
0.419
Data presented as n (%), MF: Male factor, PCO: Polycystic ovary, OF: Ovarian factor, TF: Tubal factor
Table III. Comparison of pregnancy outcomes between the two groups
Variables Prolutex group (n = 27) Vaginal progestrone group (n = 50) CI (95%) P-value
Implantation rate (%) 6/54 (11.1) 14/100 (14) -0.13- 0.76 0.587
Chemical pregnancy rate (%) 8 (29.6) 20 (40) 0.23-1.71 0.367
Clinical pregnancy rate (%) 6 (22.2) 14 (28) 0.24-2.20 0.581
Ongoing pregnancy rate (%) 6 (22.2) 14 (28) -0.36-0.37 0.581
Abortion rate (%) 2 (7.4) 6 (12) 0.31-0.55 0.791
Data are presented as n (%), Chi-squared test, CI: Confidence interval
4. Discussion
The purpose of this study was to evaluate
a new progesterone supplementation as LPS in
FET cycles, which differs from other available
preparations in dosage (25 mg/day) and manner of
administration (SC) (4). Our data analysis showed
that new SC progesterone resulted in a similar
pregnancy outcome when compared with cycles
with vaginal progesterone supplementation.
Although, many studies have investigated
the effect of different routes of progesterone
administration, most of them were directed
in fresh IVF cycles. Since there is still no
agreement on the method of use, this still
remains a controversial issue (7, 9-12). In some
literature, LPS has been continued until 10-12 wk
of gestation, however, there is a confirmation
about withdrawing P on the day of positive
pregnancy test or detection of fetal heart beat
without increasing the miscarriage rate (9, 10). So,
in our study, we administered for 8 wk in pregnant
women. Vaisbuch in a web-based universal review
showed IM progesterone utilized in 13% of IVF
cycles, whereas in North America nearly 60%
used alone or with vaginal progesterone (11).
Several observational studies showed that the
differences in efficacy due to the different forms
of progesterone administration in pregnancy
likelihood are small (12, 13). So the route of
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progesterone used for LPS did not affect the live
birth rate (14).
Lockwood and coworkers have conducted
the first large prospective randomized trial 2014
and compared Prolutex (25 mg SC daily) with
progesterone gel Crinone (90 mg intravaginal
daily) as an LPS, they showed no significant
difference in pregnancy outcomes. The ongoing
pregnancy rate per protocol in the Prolutex and
Crinone groups was 29.2% and 31.2%, respectively
(difference -2.00, 95% CI -9.12-5.13) (7).
Similarly, Baker and coworkers compared
Prolutex with vaginal progesterone inserts
(Endometrin) 100 mg twice daily in patients
undergoing fresh embryo transfer as an LPS. No
significant difference was observed in either of the
secondary end-points between the two groups (11).
Chemical pregnancy (56.4% SC vs 59.0% vaginal;
95% CI -9.5, 4.3), clinical pregnancy (42.6 vs 46.4%;
95% CI -10.8, 3.2).
The results of our study is in line with other
investigations showing that the SC aqueous
progesterone (Prolutex) 25 mg daily has an equal
effect as that of vaginal progesterone. The clinical
and ongoing pregnancy rates were 22.2% with
Prolutex and 28% with vaginal progesterone (p =
0.581), hence, no significant difference was seen
in any of the secondary outcomes, including the
implantation rate and abortion.
Although numerous examinations were done
for evaluating the reproductive outcomes of all
available types of progesterone planning for
LPS, limited studies have reflected on patient
satisfaction. Only one study has been published
so far about the patient’s acceptation of SC
progesteronewith blastocyst transfer in FET cycles;
in women that had prior experience of vaginal
progesterone, SC progesterone was related with
significantly increased receipt, but there was a
lack of data about the pregnancy outcomes in
this study (5). Vaginal progesterone has different
forms, such as capsules, gels, and pessaries. In
two studies, patients preferred vaginal gel rather
than IM injections as the former is more easier-to-
use, more contented, and more rapidly used (15).
IM progesterone causes a measurable and fixed
serum level but due to some adverse reactions
which include pain, local irritation, sterile abscess,
and limitation on self-administering it has low
patient acceptance (3, 16). The bioavailability of
Prolutex with more rapid absorption is comparable
to the IM form in serum level concentration and has
higher serum levels than vaginal progesterone (8),
however, the endometrial levels are higher when
progesterone has been used vaginally (7). Prolutex,
as mentioned earlier, can be well-tolerated and is
not painful.
Therefore, it can be suggested that for those
women who do not accept vaginal preparations
and prefer constant LPS or dislike vaginal
treatments because of social, personal, or medical
causes are also worried about the leakage of
drugs and are doubtful about the absorption of
sufficient dose. In women with vaginal bleeding,
use of a vaginal progesterone can be unpleasant
(17). All patients had the experience of SC injection
that used gonadotrophins in the hyperstimulation
cycle (11).
Finally, we remind that a large number of
investigations have been registered in the
International clinical trial and there is a lack of
information about this SC formulation in the field of
oocyte donation and FET cycles. In the near future,
we expect to face optimal finding in this context
(dose and route) that has not been well-defined,
from large, well-designed, and multicenter RCTs.
The limitations of this study are: first, restrictions
on access to Prolutex in Iran that led to reducing
the study’s sample size; second, this survey has
been done retrospectively. We assume that the
longitudinal time frame between the medication
and data record and also negative pregnancy tests
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may negatively influence women’s perception and
feelings about the drug; therefore, our patient
satisfaction was not considered.
5. Conclusion
In this study, we attempted to show that the
new SC progesterone formulation is comparable
with vaginal progesterone for LPS, there was
no statistically significant difference in pregnancy
outcomes.
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